Zura Bio Statistics
Total Valuation
Zura Bio has a market cap or net worth of $387.23 million. The enterprise value is $199.58 million.
| Market Cap | 387.23M |
| Enterprise Value | 199.58M |
Important Dates
The last earnings date was Tuesday, October 27, 2026, before market open.
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Zura Bio has 96.33 million shares outstanding. The number of shares has increased by 23.86% in one year.
| Current Share Class | 96.33M |
| Shares Outstanding | 96.33M |
| Shares Change (YoY) | +23.86% |
| Shares Change (QoQ) | +0.72% |
| Owned by Insiders (%) | 11.49% |
| Owned by Institutions (%) | 59.64% |
| Float | 45.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.18 |
| P/TBV Ratio | 2.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.29, with zero debt.
| Current Ratio | 11.29 |
| Quick Ratio | 11.06 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -63.17% and return on invested capital (ROIC) is -43.06%.
| Return on Equity (ROE) | -63.17% |
| Return on Assets (ROA) | -37.66% |
| Return on Invested Capital (ROIC) | -43.06% |
| Return on Capital Employed (ROCE) | -57.42% |
| Weighted Average Cost of Capital (WACC) | 4.30% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.06M |
| Employee Count | 40 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.30M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9.24% in the last 52 weeks. The beta is 0.01, so Zura Bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.01 |
| 52-Week Price Change | +9.24% |
| 50-Day Moving Average | 4.53 |
| 200-Day Moving Average | 5.22 |
| Relative Strength Index (RSI) | 48.03 |
| Average Volume (20 Days) | 5,080,935 |
Short Selling Information
The latest short interest is 7.02 million, so 7.29% of the outstanding shares have been sold short.
| Short Interest | 7.02M |
| Short Previous Month | 9.37M |
| Short % of Shares Out | 7.29% |
| Short % of Float | 15.40% |
| Short Ratio (days to cover) | 2.08 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -102.00M |
| Pretax Income | -94.83M |
| Net Income | -122.23M |
| EBITDA | -101.94M |
| EBIT | -102.00M |
| Earnings Per Share (EPS) | -$1.06 |
Balance Sheet
The company has $187.65 million in cash and no debt, with a net cash position of $187.65 million or $1.95 per share.
| Cash & Cash Equivalents | 187.65M |
| Total Debt | n/a |
| Net Cash | 187.65M |
| Net Cash Per Share | $1.95 |
| Equity (Book Value) | 177.66M |
| Book Value Per Share | 1.84 |
| Working Capital | 174.62M |
Cash Flow
In the last 12 months, operating cash flow was -$81.60 million and capital expenditures -$90,000, giving a free cash flow of -$81.69 million.
| Operating Cash Flow | -81.60M |
| Capital Expenditures | -90,000 |
| Depreciation & Amortization | 67,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -81.69M |
| FCF Per Share | -$0.85 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Zura Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -23.86% |
| Shareholder Yield | -23.86% |
| Earnings Yield | -26.34% |
| FCF Yield | -21.10% |
Analyst Forecast
The average price target for Zura Bio is $19.00, which is 372.64% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.00 |
| Price Target Difference | 372.64% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |